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Background: Patient reported outcomes (PROs) are especially useful in assessing treatments for rheumatoid
arthritis (RA) since they measure dimensions of health-related quality of life that cannot be captured using strictly
objective physiological measures. The aim of this study was to compare the effects of combination etanercept and
methotrexate (ETN + MTX) versus combination synthetic disease modifying antirheumatic drugs (DMARDs) and
methotrexate (DMARD +MTX) on PRO measures among RA patients from the Asia-Pacific region, a population not
widely studied to date. Patients with established moderate to severe rheumatoid arthritis who had an inadequate
response to methotrexate were studied.
Methods: Patients were randomized to either ETN + MTX (N = 197) or DMARD +MTX (N = 103) in an open-label,
active-comparator, multicenter study, with PRO measures designed as prospective secondary endpoints. The Health
Assessment Questionnaire (HAQ), Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue),
Medical Outcomes Short Form-36 Health Survey (SF-36), Hospital Anxiety and Depression Scale (HADS) and the
Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH) were used.
Results: Significantly greater improvements were noted for the ETN +MTX group at week16 for HAQ mean scores
and for proportion of patients achieving HAQ score ≤ 0.5, compared to patients in the DMARD +MTX group. SF-36
Summary Scores for physical and mental components and for 6 of 8 health domains showed significantly greater
improvements at week16 for the ETN +MTX group; only scores for physical functioning and role-emotional
domains did not differ significantly between the two treatment arms. Greater improvements at week16 were noted
for the ETN +MTX group for FACIT-Fatigue, HADS, and WPAI:GH mean scores.
Conclusion: Combination therapy using ETN +MTX demonstrated superior improvements using a comprehensive
set of PRO measures, compared to combination therapy with usual standard of care DMARDs plus MTX in patients
with established rheumatoid arthritis from the Asia-Pacific region.
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Patient reported outcomes (PROs) are increasingly recog-
nized as a scientifically valid tool for assessing the effec-
tiveness of therapy for patients with rheumatoid arthritis
(RA) [1,2]. The noteworthy impact of RA on functional
ability of the patient can result in lost productivity,
reduced social functioning and overall impaired health-
related quality of life (HRQoL) [3]. Treatment options for
patients with RA can vary according to disease severity
and duration [4,5]. Early initiation with disease modifying
anti-rheumatic (DMARD) drugs is now a mainstay of
therapy, and the stated goal of therapy is to achieve remis-
sion or the lowest possible disease activity state [6,7].
Achieving remission or a lower disease activity state can
be challenging, especially in patients with longer duration
of RA and more severe disease activity [8]. PROs are espe-
cially useful in assessing a given treatment option since
they measure dimensions of HRQoL that cannot be cap-
tured using strictly objective physiological measures [9].
Treatment options have evolved over the past few de-
cades to include biological DMARDs. Patients who have
failed to respond to therapy with synthetic DMARDs
may be considered candidates for biological DMARD
therapy [4,5]. Previous studies have shown that the fully
human anti-tumour necrosis factor (TNF) agent, etaner-
cept (ETN), alone or in combination with MTX, can sig-
nificantly improve outcomes among patients who have
failed to respond to previous therapy with synthetic
DMARDs [10-12]. Significantly improved PROs have also
been shown in trials comparing combination ETN+MTX
with ETN or MTX [13,14].
The APPEAL (Asia-Pacific Study in Patients to be Trea-
ted With Etanercept or an Alternative Listed DMARD)
trial was conducted to compare the clinical efficacy and
safety of combination ETN +MTX with combination
DMARD+MTX in patients with moderate to severe
rheumatoid arthritis from the Asia-Pacific region [15]. A
comparative efficacy trial in this population was important
since the normal practice pattern in the region is to start
biologics after failure of several DMARDs. Results showed
that ETN +MTX in patients with moderate to severe
rheumatoid arthritis from the Asia-Pacific region showed
superior efficacy compared with usual DMARD+MTX
regimens, with similar safety profiles. The objective of the
present study was to report the PROs captured in the AP-
PEAL trial.
Methods
The APPEAL trial was a Phase 4, 16-week, randomized,
open-label, active-comparator, parallel-design, outpatient,
multicenter study conducted in the Asia-Pacific region,
the primary objective of which was to compare efficacy
and safety of ETN+MTX with usual DMARD+MTX.
The trial was conducted at sites in Hong Kong, India,Malaysia, Philippines, Taiwan, Korea and Thailand be-
tween June 2007 and March 2009. Details of the patient
population, inclusion and exclusion criteria, and primary
and secondary clinical efficacy results are summarized
throughout this manuscript and reported in full elsewhere
[15]. PROs reported here are prospective secondary end-
points from patients forming the modified intent to treat
(mITT) population enrolled in the two treatment groups
of the APPEAL study.
Written informed consent was obtained from all patients
prior to enrollment. This study was conducted in accor-
dance with the International Conference on Harmonisation
Guideline for Good Clinical Practice and the ethical prin-
ciples that have their origins in the Declaration of Helsinki.
Written approval was obtained from Independent Ethics
Committees/Institutional Review Boards at each institution
participating in the study.
Patients
The APPEAL study enrolled patients aged 18–69 years at
time of consent with active moderate to severe RA, based
on 1987 ACR criteria [16] and 28-joint Disease Activity
Score [DAS28] ≥3.2, who displayed inadequate response
to oral MTX (stable dosing between 7.5 mg/week and 25
mg/week for minimum 3 months) at screening. Patients
were randomized to either of two treatment groups in an
approximate 2:1 ratio: ETN+MTX (N = 197) or to
DMARD+MTX (N= 103). ETN was administered sub-
cutaneously (25 mg per injection) twice weekly. The dose
and administration of usual DMARD therapy (defined as
the addition of DMARD investigator’s choice to MTX)
followed the standard of care and approved local label
or recommendations; the three most frequently used
DMARDs in the study were leflunomide (n = 69), sulfa-
salazine (n = 23) and hydroxychloroquine (n = 11). MTX
was to be taken orally once weekly as a single dose or in
two divided doses on the same day (per local label) and
was continued at the same dose throughout the study as
at the time of screening (N = 300). Folic acid supplementa-
tion was recommended to all patients to minimize side
effects associated with MTX.
Patient reported outcomes instruments
Five instruments were used to evaluate health- and qua-
lity of life-related PROs. The Health Assessment Ques-
tionnaire (HAQ) assesses functional ability for eight
subscales: arising, common daily activities, dressing and
grooming, eating, grip, hygiene, reach and walking. The
HAQ subscales range from 0 (no difficulty) to 3 (unable
to do). The Medical Outcomes Short Form-36 (SF-36)
Health Survey assesses health related quality of life in
eight domains: bodily pain, general health, physical func-
tioning, role-physical, mental health, role-emotional,
social functioning and vitality. SF-36 scores range from 0
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SF-36 Physical Component Summary scores comprise
scores from bodily pain, general health, physical func-
tioning and role physical domains while Mental Compo-
nent Summary scores are derived from mental health,
role-emotional, social functioning and vitality domains.
The Hospital Anxiety and Depression Scale (HADS) is
comprised of 7 items each for assessing clinically signifi-
cant anxiety and depression with possible scores from 0
(best) to 3 (worst) [17]. The Functional Assessment of
Chronic Illness Therapy Fatigue (FACIT-Fatigue) Scale
Scores range from 0 to 52, with higher scores indicating
less fatigue [18]. The Work Productivity and Activity
Impairment Questionnaire: General Health (WPAI:GH)
instrument measures percentage impairment of usual
activities and percentage impairment of work and prod-
uctivity due to health, with higher scores reflecting
higher percentage impairment [19]. Assessments were
carried out at baseline, at week 8 and at week 16
(reported here for week 16). Validated translations of
instruments, where available, were used in the various
countries based on primary language requirements.
English versions were used in those countries where
feasible.
Data analysis
Patient reported outcomes data were analyzed from the
mITT population, consisting of all patients who received
at least one dose of study drug (ETN or DMARD) in
combination with MTX and submitted at least one post-
baseline assessment. Missing data were imputed using
the last observation carried forward (LOCF) method for
HAQ scores. Data presented for WPAI:GH scores were
analyzed using observed cases only. Analysis of cova-
riance was used to compare changes in continuous PRO
variables from baseline between treatment groups (ETN
+MTX versus DMARD +MTX). Pair-wise comparisons
using ANCOVA were adjusted for baseline scores, coun-
try and treatment effects. Response proportions were
analyzed using the Cochran-Mantel-Haenszel test, strati-
fied by country.
Results
A total of 300 patients were enrolled, 197 of whom were
randomized to ETN+MTX and 103 to DMARD+MTX.
There were 19 discontinuations, 4 (2%) from the ETN +
MTX group and 15 (14.6%) from the DMARD+MTX
group and thus 281 patients (93.7%) completed the
16-week study [15]. Demographic and baseline disease
characteristics were not significantly different between the
two treatment groups; patients were entirely of Asian
ethnicity, mainly female (91.4% and 88.4% for ETN +
MTX and DMARD+MTX groups, respectively) and of
mean age (± SD) 48.4 years ± 12.0 and 48.5 years ± 11.3,respectively [15]. Mean disease duration in years (±SD)
was 6.5 ± 7.3 and 6.9 ± 8.5, respectively [15]. Mean weekly
dosage (range) of MTX was 12.9 mg (1.9-25.0). Prior
DMARD use, other than MTX, was reported in 24.4% and
30.1% of patients [15].
Above the improvements on clinical efficacy measures
with ETN +MTX compared to DMARD +MTX that
were recently reported [15] and that are summarized in
the discussion below, patients receiving ETN +MTX
reported significantly greater improvements in all five
instruments used to assess functional ability through
PRO measures compared to patients receiving DMARD+
MTX. Mean HAQ scores at baseline were comparable
between ETN +MTX and DMARD +MTX groups at
1.37 ± 0.68 and 1.41 ± 0.67, respectively (P = 0.592), but
by week 16, the mean HAQ score had improved by
49.4% to 0.69 with ETN +MTX whereas the DMARD+
MTX group mean HAQ score had improved by 38.3% to
0.87 (P = 0.025; Table 1). Using a cut-off value of 0.5 in
HAQ scores, which signifies a score representative of the
general population, at baseline, 14.2% of ETN +MTX
patients and 12.6% of DMARD+MTX patients had mean
HAQ scores ≤ 0.5 (P = 0.86), whereas at week 16, 51.8% of
ETN +MTX patients and 39.0% of DMARD+MTX
patients had mean HAQ scores ≤ 0.5 (P = 0.048). In a sub-
group analysis of patients with ≤ 12 months of disease dur-
ation at baseline (not shown in Table 1), 55.8% of ETN +
MTX patients at week 16 had mean HAQ scores ≤ 0.5
compared with 41.0% of DMARD+MTX patients
(P = 0.031).
Summary measures of physical and mental health
items from the SF-36 instrument are also presented in
Table 1. Mental and physical component summary
scores were both similar between the two groups at
baseline. At week 16, physical component summary
scores had improved by 10.0 points (31.4%) and 7.1
points (22.8%) in the ETN +MTX and DMARD +MTX
groups, respectively, while mental component summary
scores were improved by 7.3 points (17.5%) and 5.4
points (13.3%), respectively. The improvements were
significantly greater among the ETN +MTX patients
compared to DMARD +MTX patients for both physical
(P = 0.003) and mental (P = 0.047) component summa-
ries. In terms of individual SF-36 domains, mean SF-36
scores were significantly higher for the ETN +MTX
group compared to the DMARD +MTX group for six of
eight domains; the two domains where improvements
were similar between the two treatment groups were
physical functioning and role limitations-emotional
(Figure 1). Within the ETN +MTX group, the greatest
percentage improvements from baseline were observed
for: role limitations-physical (195%), role limitations-
emotional (82%), bodily pain (72%) and general health
(55%) (Figure 1).
Table 1 Health assessment questionnaire and short form-36 physical and mental component summary scores
Instrument/ ETN +MTX DMARD +MTX P value
Time on therapy
HAQ Score Mean Score (% Improvement from Baseline) (N)
Baseline 1.37 (0%) (N = 197) 1.41 (0%) (N = 103)
Week 16 0.69 (49.4%) (N = 193) 0.87 (38.3%) (N = 100) 0.025*
HAQ Proportion Patients achieving HAQ Score ≤ 0.5, Proportion (%)
Baseline 28/197 (14.2%) 13/103 (12.6%)
Week 16 100/193 (51.8%) 39/100 (39.0%) 0.048**
SF-36 Physical Component Summary Scores Mean Score (% Improvement from Baseline) (N)
Baseline 30.5 (0%) (N = 193) 30.1 (0%) (N = 100)
Week 16 40.4 (31.4%) (N = 189) 37.3 (22.8%) (N = 96) 0.003*
SF-36 Mental Component Summary Scores Mean Score (% Improvement from Baseline) (N)
Baseline 42.9 (0%) (N = 193) 42.4 (0%) (N = 100)
Week 16 50.2 (17.5%) (N = 189) 47.8 (13.3%) (N = 96) 0.047*
Scores at Baseline and Following 16 Weeks of Therapy in Asia-Pacific Rheumatoid Arthritis Patients Treated With ETN +MTX versus DMARD +MTX
(Last Observation Carried Forward Analysis).
DMARD: Disease Modifying Antirheumatic Drug; ETN: etanercept; FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy- Fatigue; HAQ: Health
Assessment Questionnaire; MTX: methotrexate; SF-36: Medical Outcomes Short Form-36 Health Survey.
Values have been rounded.
*ANCOVA, considering the factors ‘baseline score + therapy + country’.
**Cochran-Mantel-Haenszel Test.
Bae et al. BMC Musculoskeletal Disorders 2013, 14:13 Page 4 of 8
http://www.biomedcentral.com/1471-2474/14/13Mean and percentage improvements in the HADS
are shown in Table 2. Statistically significant greater
improvements were observed in the ETN +MTX pa-
tient group compared to the DMARD +MTX group in
Anxiety subscale scores—29.1% improvement versus
18.5% improvement, respectively (P = 0.026) as well as




















Figure 1 Short Form-36 Individual Domain Scores. Scores at Baseline a
DMARD +MTX (Last Observation Carried Forward Analysis).16.4% improvement, respectively (P = 0.016). Both groups
reported similar fatigue rating scores at baseline using the
FACIT-Fatigue instrument, however the mean percentage
improvement in the FACIT-Fatigue scale was significantly
greater in the ETN +MTX group compared with the
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Table 2 Hospital anxiety and depression scale scores and functional assessment of chronic illness therapy-fatigue
scores
Instrument/ ETN +MTX DMARD+MTX P Value*
Time on therapy Mean Score (% Improvement from Baseline) (N)
Anxiety Subscale
Baseline 8.27 (0%) (N = 196) 8.19 (0%) (N = 103)
Week 16 5.84 (29.1%) (N = 192) 6.69 (18.5%) (N = 100) 0.026
Depression Subscale
Baseline 7.62 (0%) (N = 196) 7.85 (0%) (N = 103)
Week 16 5.42 (28.7%) (N = 192) 6.56 (16.4%) (N = 100) 0.016
FACIT-Fatigue
Baseline 28.1 (0%) (N = 146) 30.1 (0%) (N = 76)
Week 16 36.2 (28.0%) (N = 143) 33.2 (10.4%) (N = 73) 0.001
Scores at Baseline and Following 16 Weeks of Therapy in Asia-Pacific Rheumatoid Arthritis Patients Treated With ETN +MTX versus DMARD +MTX
(Last Observation Carried Forward Analysis).
DMARD: Disease Modifying Antirheumatic Drug; ETN: etanercept; FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy- Fatigue; MTX: methotrexate.
*ANCOVA, considering the factors ‘baseline score + therapy + country’.
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tionnaire was used to quantitatively assess percentage im-
pairment of usual activities among all patients, as well as
work- and productivity-related effects of RA on that por-
tion of both groups who were employed (Table 3). Both
groups reported similar percent usual activity impairment
(approximately 59%) due to health at baseline (Table 3;
P = 0.983). At week 16, percent usual activity impairment
due to health declined to 41% in the DMARD+MTX
group and to 30% in the ETN+MTX group, a significant
difference between the two groups based on all patients
(P < 0.001). Employed patients comprised approximately
30% of patients from both groups who reported outcomes
at week 16. In this sub-group, significant improvementsTable 3 Work productivity and activity impairment questionn
Instrument Subscale/ ETN +MTX
Time on Therapy Mean Score (% Imp
Percent activity impairment due to health
Baseline 58.6 (0%) (N = 197)
Week 16 30.0 (48.7%) (N = 186)
Percent impairment while working due to health problem
Baseline 48.9 (0%) (N = 62)
Week 16 24.1 (49.6%) (N = 54)
Percent overall work impairment due to health problem
Baseline 52.3 (0%) (N = 61)
Week 16 25.1 (51.0%) (N = 53)
Percent work time missed due to health
Baseline 10.6 (0%) (N = 63)
Week 16 2.04 (80.7%) (N = 55)
General Health at Baseline and Following 16 Weeks of Therapy in Asia-Pacific Rheum
(Observed Case Analysis).
DMARD: Disease Modifying Antirheumatic Drug; ETN: etanercept; MTX: methotrexat
*ANCOVA, considering the factors ‘baseline score + therapy + country’.were noted at week 16 for all three indicators of work pro-
ductivity. Notably, overall mean work impairment due to
health problems was reduced from 52.3% to 25.1% in the
ETN+MTX group whereas the reduction in the DMARD+
MTX group was smaller, from 56.3% to 41.6% (P = 0.004,
Table 3). Work time missed due to health was reduced by
80.7% in the ETN+MTX group at week 16, while the
DMARD+MTX group reported an average reduction of
missed work time of 21.7% at week 16 (P = 0.002,Table 3).
Discussion
The APPEAL trial compared efficacy, safety and PROs
with ETN +MTX versus DMARD +MTX in patients
from Asia-Pacific countries with moderate to severe RA,aire
DMARD+MTX P value*
rovement from Baseline) (N)
58.6 (0%) (N = 103)
41.0 (29.3%) (N = 83) < 0.001
51.4 (0%) (N = 37)
37.3 (23.6%) (N = 26) 0.012
56.3 (0%) (N = 37)
41.6 (22.0%) (N = 26) 0.004
14.9 (0%) (N = 37)
10.7 (21.7%) (N = 26) 0.002
atoid Arthritis Patients Treated With ETN +MTX versus DMARD +MTX
e.
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response to MTX monotherapy for a minimum of three
months. Detailed results of primary clinical endpoints
for ETN+MTX versus DMARD+MTX groups, reported
by Kim and colleagues[15], showed significantly greater
ACR response area under the curve, proportion of
subjects achieving ACR 20, 50 and 70 responses at
Week 16, numbers achieving low disease activity scores
(DAS28 < 3.2), and improvements in DAS28 score, pain
visual analogue scale, the health assessment question-
naire, and physician and patient global assessments.
Results in the same subjects on health outcomes eva-
luations, presented here, demonstrate that in addition
to improvements in objective clinical measures of dis-
ease activity, combination therapy with ETN +MTX
provided statistically significant and clinically meaning-
ful improvements in PROs compared to combination
therapy using MTX and usual DMARDs.
The mean HAQ scores at baseline were not significantly
different between the two groups and both groups of
patients reported significant improvements. Slightly more
than half (52%) of patients on ETN+MTX achieved a
HAQ score lower than 0.5 at week 16, which is representa-
tive of the general population, compared to 39% of patients
on DMARD+MTX. Furthermore, the ETN+MTX group
improved their mean HAQ scores by 49% compared to
38% for the DMARD+MTX group. Two other trials
reporting on HAQ scores with MTX/ETN combination
therapy have reported percentage improvements in HAQ
scores of approximately 50-60% over a period of 52 weeks
[13,14]. By way of comparison, Kosinski et al. concluded
from a study of rheumatoid arthritis patients that an aver-
age percentage improvement of 27% in HAQ scores was
clinically significant and could be correlated with meaning-
ful changes in other disease severity indicators such as joint
swelling and tenderness counts, patient and physician
global assessments, and pain [9].
Rheumatoid arthritis patients generally report higher
levels of severe fatigue that can exacerbate other symptoms
of the disease, worsen physical and emotional well-being
and interfere with employment, social and family opportun-
ities and obligations [20,21]. Fatigue is a common and de-
bilitating symptom in RA patients and both the American
College of Rheumatology and European League Against
Rheumatism have highlighted the need for more informa-
tion on fatigue from clinical trials, using validated fatigue
scales [22]. Both arms in this study reported a lessening of
fatigue symptoms as measured using the FACIT-Fatigue in-
strument, however, the ETN+MTX arm showed a signifi-
cantly larger reduction of fatigue symptoms after 16 weeks
(8 points or 28% improvement) compared to the DMARD
+MTX arm (3 points or 10.4% improvement). The clinical
significance of this reduction can be understood through a
comparison with other studies that have assessed themagnitude of changes in the FACIT-Fatigue scale that are
associated with minimal clinically important differences in
RA patients. Cella et al. [18] estimated a distribution-based
minimally important difference in FACIT-Fatigue scores of
4.1, whereas Pouchot et al. [23] estimated a regression-
based minimal clinically important difference of 8.3 points
on the FACIT-Fatigue 52 point scale, which was used in
our study.
The mean physical and mental health component
summary scores derived from the SF-36 were not differ-
ent between the two arms at baseline. However, after 16
weeks, both scores improved by a higher percentage for
patients randomized to ETN +MTX compared to those
on DMARD +MTX. Improvement in absolute score for
the ETN +MTX group was higher by a magnitude of
2.7 points for the physical component summary, which
is within the range of an accepted minimally clinically
important difference (MCID) of 2.5-5 [24]. The mean for
mental component score, however, did not meet that
threshold. Improvement for the ETN +MTX group was
higher than the DMARD+MTX group for six of the eight
domain scores by a magnitude within a range of what is
considered a MCID for individual domains (5–10 points)
[25]. The two domains that did not meet the MCID
threshold are mental health and physical functioning.
Not surprisingly, anxiety and depression coexist with RA
and tend to be positively correlated with disease severity
and duration [26]. A previous study of patients with early
RA indicated that anxiety and depression were improved,
along with other PRO measures, with ETN +MTX and
that these were associated with achieving clinical remission
[13]. The significantly greater improvements in the HADS
measures for patients on ETN+MTX thus reflect the con-
sistently more positive outcomes in this subject group seen
in the other PRO measures. These improvements in func-
tional ability and psychological well-being were further
confirmed through a positive impact on work productivity
and activity as measured by WPAI:GH. The percentage
activity impairment due to health in all patients, as
assessed by the WPAI:GH instrument, was improved more
substantially in the ETN+MTX group compared to the
DMARD+MTX group, by 49% compared to 29%, re-
spectively. In a subgroup of patients who were employed
upon enrollment, the WPAI:GH instrument showed an
81% improvement in missed time from work due to health
in the ETN+MTX group, compared to a 22% improve-
ment in missed time in DMARD+MTX arm.
There are limitations to this study and the analysis of
PRO data. Since the APPEAL trial used an open-label
study design, these PRO results may be considered less
rigorous than a blinded study. However, this design
allowed comparison of combination therapy approaches
that incorporated the usual standard of care (synthetic
DMARDs) versus ETN in routine clinical settings. The
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sidered a limitation; however this is longer than the
3-month period recommended by EULAR for assess-
ment of current treatment failure or success for RA.
Thus, results from the 16 week follow-up period are
valid in informing clinical decision making. Further, this
study included patients who had not improved while on
methotrexate for at least three months, thus the results
may not be generally applicable to, for example,
DMARD naïve patients. It is however interesting that
similar improvements in HAQ and SF-36 scores were
demonstrated over 52 weeks in patients from the
COMET trial with early RA (mean disease duration of 9
months) [13]. Lastly, the subject population comes from
a limited number of countries in this region and may
not be generalizable to the entire region or even to all
countries studied due to the limited sample size.
Conclusions
The APPEAL trial provides an evidence base that
addresses two gaps in the published literature concern-
ing TNF inhibitor therapy for treatment of RA. First,
there is a lack of data on TNF inhibitor therapy from
clinical trials originating from the Asia-Pacific region,
and second, there is a recognized lack of head-to-head
trials comparing outcomes from combination therapies
involving synthetic versus biologic DMARDs [27]. This
study extends the findings regarding the impact of
combination therapy using ETN and MTX on a compre-
hensive set of PRO measures in patients from the Asia-
Pacific region with established rheumatoid arthritis, and
reinforces the efficacy of ETN +MTX in these patients.
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